• The study compound may potentially be used for the treatment of brain disorders. By blocking a certain protein in the brain, the study compound may help reduce harmful brain inflammation. This blockage can also improve the information transfer between brain cells. The study compound will be administered once by mouth on the day after admission in the research center. A small amount of alcohol is used in the composition of the study compound.
• This is a clinical trial with a radioactive (14C) labeled compound. Radioactively labeling a compound is done to be able to study how quickly and to what extent the compound is absorbed, converted and excreted by the body. The radioactivity disappears from the body at the same time as the compound through the feces, urine and/or breath. The compound has a negligible radiation burden which is less than from the natural background radiation that you are exposed to in the Netherlands in 2-3 months. This background radiation is released from space, soil, air, water, food and construction materials. To measure radioactivity levels in your body, blood, urine and feces will be collected during the trial.

Tested more frequently:

The compound has already been tested in healthy individuals. The compound has been given to 474 participants in 10 previous trials. In these trials the compound was generally safe and well tolerated, the following side-effects were observed: headache and temporary reduction in the number of platelets (blood cells that help with clotting). You may also experience other, yet unknown, side effects. Prior to the medical screening, you will receive written information about the trial, which also describes the possible side effects. This information will also be discussed with you at the start of the medical screening. You can then ask the screening physician or nurse any questions you may have. Once everything is clear to you, you can decide whether to give written consent to participate in the trial. The medical screening will only take place after you have given written consent to participate in the trial. We want to emphasize that even after giving written consent, participation in any clinical trial is voluntary. You can decide at any time not to participate or to stop the medical screening or the trial. You do not need to provide a reason for why you no longer wish to participate.

You will receive a gross compensation of € 4.811,- for participation in this clinical trial. For each 24-hour visit that is needed you will receive an additional compensation of € 278,-.

Travel expenses will be reimbursed based on the distance traveled (€ 0.23 per kilometer) with a minimum of € 14.23 and a maximum of € 193.20 (840 kilometers) per round trip, regardless of the mode of transportation.